Event-Driven Stocks

Allogene Therapeutics, Inc.

ALLONasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 2 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$0$22,000$95,000$39,000$114.1M$0
Operating income−$209.3M−$273.2M−$327.7M−$80.0M−$180.2M−$258.2M
Net income−$190.9M−$257.6M−$327.3M−$78.6M−$182.1M−$250.2M
Total assets$415.9M$548.7M$642.8M$978.1M$1.04B$1.23B
Total liabilities$123.4M$126.5M$130.6M$112.8M$122.2M$148.2M
Equity$292.5M$422.2M$512.2M$666.9M$925.2M$1.01B
EPS (diluted)$-0.87$-1.32$-2.09$-0.56$-1.34$-2.08
Shares out.217.3M169.1M144.5M142.8M140.6M124.9M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−65.3%
Return on assets
−45.9%
Return on capital (ROCE)
−54.6%
Liabilities / assets
29.7%
Debt / equity
0.42×
Book value / share
$1.35
Revenue growth (YoY)
−100.0%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-13.10distress
Accruals / assets
−10.0%clean
Piotroski F-Score
2/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
42
/ 100
Profitability 0Growth 0Catalyst 67Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 1 severe● 2 warning● 2 good
  • Altman Z″ in the distress zone
  • Revenue declined year-over-year
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202642.3M6.4+14.7%
Apr 30, 202636.9M3.7+1.3%
Apr 15, 202636.4M1.6+13.5%
Mar 31, 202632.1M4.8+31.3%
Mar 13, 202624.4M6.2+2.1%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.